Vaxcyte is emerging as a leader in vaccine innovation, leveraging high-fidelity vaccines to combat bacterial diseases. The company's lead candidate, VAX-24, demonstrated robust immune responses and a ...
Vaxcyte recently reported further progress on its next-generation 31-valent pneumococcal conjugate vaccine VAX-31, including first dosing in the adult OPUS-2 Phase 3 trial, completion of enrollment in ...
Comprehensive VAX-31 Adult Phase 3 Clinical Program, Finalized in Consultation and Alignment with FDA, Advances with Three Phase 3 Studies ...
The last time I spoke about Vaxcyte, Inc. (PCVX) it was in a Seeking Alpha article entitled "Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling." With respect to this article, I noted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results